Jones Financial Companies’s Inhibrx INBX Stock Holding History

Jones Financial Companies’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4	Closed	-$56	–	4101
2025 Q1	$56	Buy	+4	New	+$54	﹤0.01%	3648

Other funds holding INBX

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Jones Financial Companies's INBX Position: Q2 2025 in Review

Jones Financial Companies sold out of Inhibrx (INBX) in Q2 2025, closing a stake of 4 shares — an estimated $56 sold.

Jones Financial Companies first reported a position in INBX in Q1 2025 and held it in 1 quarter. The position peaked at $56 in Q1 2025. 88 funds tracked by Wall St. Rank hold INBX as of Q2 2025.

Jones Financial Companies reported no remaining Inhibrx position as of Q2 2025 after selling out during the quarter.
Jones Financial Companies sold 4 Inhibrx shares in Q2 2025, an estimated $56.
Jones Financial Companies first reported a position in Inhibrx in Q1 2025 and held it in 1 quarter.
Jones Financial Companies's Inhibrx position peaked at $56 in Q1 2025.
88 funds tracked by Wall St. Rank held Inhibrx as of Q2 2025.

Based on Jones Financial Companies's 13F filing for Q2 2025, filed 13 Aug 2025.